

16. Fedor M, Samoš M, Šimonová R, et al. Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay. *Clin Appl Thromb Hemost* 2015; 4: 334–338.
17. Samoš M, Fedor M, Kovář F, et al. Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? *Blood Coagul Fibrinolysis* 2016; 2: 117–120.
18. Bolek T, Samoš M, Šimonová R, et al. Does Pantoprazole Affect the On-Treatment Platelet Reactivity in Patients With Acute STEMI Treated With ADP Receptor Blockers? A Pilot Prospective Study. *Am J Ther* 2017; 2: e162–e166.
19. Mueller T, Dieplinger B, Poelz W, et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer – comparison with two flow cytometric methods. *Thromb Res* 2007; 121: 249–258.
20. Velik-Salchner C, Maier S, Innerhofer P, et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. *Anesth Analg* 2008; 107: 1798–1806.
21. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. *J Am Coll Cardiol* 2009; 53: 849–856.
22. Consuegra-Sánchez L, López-Palop R, Cano P, et al. Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays. *J Thromb Haemost* 2013; 2: 379–381.
23. Verdoia M, Barbieri L, Suryapranata H, et al. Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. *Platelets* 2016; 27: 93–104.
24. Lundström A, Wallén H, von Arbin M, et al. Clopidogrel Resistance after Minor Ischemic Stroke or Transient Ischemic Attack is Associated with Radiological Cerebral Small-Vessel Disease. *J Stroke Cerebrovasc Dis* 2015; 10: 2348–2357.
25. Bernlochner I, Jaitner J, Fries V, et al. High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease. *Vasa* 2016; 45: 155–161.
26. Shim CY, Yoon SJ, Park S, et al. The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. *Int J Cardiol* 2009; 134: 351–355.
27. Pinto Slottow TL, Bonello L, Gavini R, et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. *Am J Cardiol* 2009; 104: 525–530.
28. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. *J Am Coll Cardiol* 2009; 53: 1101–1109.
29. Campo G, Fileti L, de Cesare N, et al. 3T/2R Investigators. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. *J Am Coll Cardiol* 2010; 56: 1447–1455.
30. Jang J, Lim J, Chang K, et al. A comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y₁₂ assay for the assessment of clopidogrel resistance in patients undergoing percutaneous coronary intervention. *J Clin Lab Anal* 2012; 26: 262–266.
31. Fifi JT, Brockington C, Narang J, et al. Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. *AJNR Am J Neuroradiol* 2013; 34: 716–720.
32. Nordeen JD, Patel AV, Darracott RM, et al. Clopidogrel Resistance by P2Y₁₂ Platelet Function Testing in Patients Undergoing Neuroendovascular Procedures: Incidence of Ischemic and Hemorrhagic Complications. *J Vasc Interv Neurol* 2013; 6: 26–34.
33. Leunissen TC, Peeters Weem SM, Urbanus RT, et al. High On-Treatment Platelet Reactivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Values. *Eur J Vasc Endovasc Surg* 2016; 52: 198–204.
34. Collet JP, Cuisset T, Rangé G, et al. ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. *N Engl J Med* 2012; 367: 2100–2109.
35. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. *J Am Coll Cardiol* 2012; 59: 2159–2164.
36. Bagai A, Peterson ED, McCoy LA, et al. Association of measured platelet reactivity with changes in P2Y₁₂ receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the Treatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. *Am Heart J* 2017; 187: 19–28.
37. Jung HJ, Sir JJ. Recurrent myocardial infarction due to one subacute and two very late thrombotic events of drug-eluting stent associated with clopidogrel resistance. *J Invasive Cardiol* 2011; 23: E15–E18.
38. Bouman HJ, van Werkum JW, Breet NJ, et al. A case-control study on platelet reactivity in patients with coronary stent thrombosis. *J Thromb Haemost* 2011; 9: 909–916.
39. Rajendran S, Parikh D, Shugman I, et al. High on treatment platelet reactivity and stent thrombosis. *Heart Lung Circ* 2011; 20: 525–531.
40. Gaglia MA, Torguson R, Pakala R, et al. Correlation between light transmission aggregometry, VerifyNow P2Y₁₂, and VASP-P platelet reactivity assays following percutaneous coronary intervention. *J Interv Cardiol* 2011; 24: 529–534.
41. Fedor M, Šimonová R, Fedorová J, et al. Role of VASP phosphorylation assay in monitoring the antiplatelet therapy. *Acta Medica Martiniana* 2013; 13: 21–26.
42. Bouman HJ, Parlak E, van Werkum JW, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. *J Thromb Haemost* 2010; 8: 482–488.
43. Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. *J Thromb Haemost* 2005; 3: 85–92.
44. Remková A, Janušicová A, Remko M. Is antiplatelet therapy always effective? *Vnitř Lék* 2012; 58: 904–914.
45. Cuisset T, Frere C, Quilici J, et al. Role of the T744C polymorphism of the P2Y₁₂ gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. *Thromb Res* 2007; 120: 893–899.
46. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. *J Am Coll Cardiol* 2008; 51: 1404–1411.
47. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. *J Thromb Haemost* 2007; 5: 1630–1636.
48. Cuisset T, Frere C, Poyet R, et al. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. *Arch Cardiovasc Dis* 2010; 103: 39–45.
49. El Ghannudi S, Ohlmann P, Meyer N, et al. Impact of P2Y₁₂ inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry. *JACC Cardiovasc Interv* 2010; 3: 648–656.
50. Zhang S, Lai X, Li W, et al. VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke. *Thromb Res* 2014; 134: 1272–1277.
51. Ari H, Ozkan H, Karacinar A, et al. The Effect of high-dose Clopidogrel treatment in patients with clopidogrel resistance (the EFFICIENT trial). *Int J Cardiol* 2012; 157: 374–380.
52. Collet JP, Hulot JS, Anzaha G, et al. CLOVIS-2 Investigators. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). *JACC Cardiovasc Interv* 2011; 4: 392–402.
53. Choi H, Ryu J, Seo H, et al. Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients? *Int J Clin Pharm* 2015; 37: 758–761.
54. Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y₁₂ assay: Impact on Thrombosis and Safety (GRAVITAS) trial. *Circulation* 2011; 124: 1132–1137.
55. Diodati JG, Saucedo JF, Cardillo TE, et al. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. *Thromb Haemost* 2014; 112: 311–322.
56. Valenti R, Marcucci R, Comito V, et al. Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to Clopidogrel and StEnt Thrombosis). *JACC Cardiovasc Interv* 2015; 8: 1563–1570.
57. Park SD, Lee MJ, Baek YS, et al. Randomised trial to compare a protective effect of Clopidogrel Versus Ticagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial). *EuroIntervention* 2016; 12: e964–e971.
58. Yao G, Su G, Li K, et al. Comparative study of ticagrelor and clopidogrel in therapeutic effect of acute myocardial infarction patients undergoing percutaneous coronary intervention. *Saudi J Biol Sci* 2017; 24: 1818–1820.
59. Sardella G, Calcagno S, Mancone M, et al. Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial. *Int J Cardiol* 2015; 194: 60–62.
60. Behr T, Kuch B, Behr W, et al. Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. *Clin Res Cardiol* 2011; 100: 907–914.
61. Kim BK, Oh SJ, Yoon SJ, et al. A randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention. *Yonsei Med J* 2011; 52: 717–726.
62. Ha SJ, Kim SJ, Hwang SJ, et al. Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention. *Coron Artery Dis* 2013; 24: 690–697.